Placeholder Banner

EU’s Anti-Science Comitology Reform Threatens Innovation

February 14, 2017

The Biotechnology Innovation Organization (BIO) issues the following statement in response: 

“BIO is extremely discouraged by the European Commission’s new proposal to alter voting procedures regarding product authorizations, such as import authorizations for GMOs.
  

“This process, known as Comitology, has been broken for years because it allows politics to undermine the risk assessment function of the European Food Safety Authority (EFSA) and other independent European risk assessment agencies. However, with this proposal the Commission is attempting to shift responsibilities back to the Member States rather than working towards building confidence and consensus in support of the independent scientific opinions of EFSA. 
 

“This proposal adds substantial uncertainty regarding the future of EU import approvals for GMO crops and the ability of Europe’s food chain to have access to a reliable and safe supply of high quality imported grains and oilseeds.  Further, this move sends yet another message that Europe has no interest in encouraging investment and innovation in agricultural technologies.”  

Discover More
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…